ProKidney (NASDAQ: PROK) director plans sale after trust offloads 229K

Rhea-AI Filing Summary

ProKidney Corp. (PROK) received a Rule 144 notice indicating that director Brian Pereira plans to sell common stock. The notice lists a planned sale of 114,000 shares of common stock of ProKidney through Merrill Lynch Pierce Fenner and Smith on NASDAQ. It also discloses that a related holder, the Brian Pereira 2012 Irrevocable Trust, has sold 229,338 shares of ProKidney common stock over the past three months for $314,462.14.

Key Figures

Planned shares to be sold: 114,000 shares Shares sold in past 3 months: 229,338 shares Proceeds from past 3 months sales: $314,462.14 +2 more

5 metrics

Planned shares to be sold 114,000 shares Common stock of ProKidney Corp. to be sold under Rule 144

Shares sold in past 3 months 229,338 shares ProKidney common stock sold by Brian Pereira 2012 Irrevocable Trust

Proceeds from past 3 months sales $314,462.14 Aggregate consideration for 229,338 shares sold by the trust

Profits Interests acquired 81,929 Profits Interests in ProKidney Corp. acquired on 01/17/2022 for cash

Acquisition date of Profits Interests 01/17/2022 Date of cash acquisition of 81,929 Profits Interests

Key Terms

Rule 144, Profits Interests, Irrevocable Trust, NASDAQ

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Profits Interests financial

"Common | 01/17/2022 | Profits Interests | ProKidney Corp"

Irrevocable Trust financial

"Brian Pereira 2012 Irrevocable Trust C/O Prokidney Corp"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

NASDAQ market

"208926941 | 08/18/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

What does the Form 144 filing for PROK disclose about Brian Pereira?

The Form 144 shows that director Brian Pereira intends to sell 114,000 shares of ProKidney Corp. (PROK) common stock through a broker on NASDAQ. It also identifies him as the person for whose account the securities are to be sold.

How many PROK shares are planned to be sold under this Form 144?

The notice indicates a planned sale of 114,000 shares of ProKidney Corp. common stock. These shares are to be sold through Merrill Lynch Pierce Fenner and Smith, with the securities listed for trading on NASDAQ.

Were any PROK shares sold in the three months prior to this Form 144?

Yes. The filing states that the Brian Pereira 2012 Irrevocable Trust sold 229,338 shares of ProKidney common stock during the past three months, for aggregate proceeds of $314,462.14, with the trust address shown care of ProKidney Corp.

What prior acquisition of securities related to PROK is disclosed in this Form 144?

The filing reports an acquisition of 81,929 securities described as Profits Interests in ProKidney Corp. on 01/17/2022 for cash. This information appears in the section describing the securities to be sold and their acquisition details.

On which market are the PROK shares in this Form 144 intended to be sold?

The shares referenced in the Form 144 are identified as trading on NASDAQ. The broker listed for the planned sale is Merrill Lynch Pierce Fenner and Smith, located at 100 Federal Street, 12th Floor, Boston, Massachusetts 02110.

Who is the selling broker named in the PROK Form 144?

The planned sale of ProKidney Corp. common stock is shown as being handled by Merrill Lynch Pierce Fenner and Smith. Their address is listed as 100 Federal St, 12th Fl, Boston, MA 02110 in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:41 PM Accepted by SEC EDGAR 08/18/2026 - 04:41 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001298146
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ProKidney Corp
SEC File Number
Address of Issuer	3929 W Pt Blvd #G Winston-Salem NORTH CAROLINA 27103
Phone	866-955-4394
Name of Person for Whose Account the Securities are To Be Sold	Brian Pereira
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch Pierce Fenner and Smith 100 Federal St 12th Fl Boston MA 02110	81929	114000	208926941	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/17/2022	Profits Interests	ProKidney Corp			81929	01/17/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Pereira 2012 Irrevocable Trust C/O Prokidney Corp 3929 Westpoint Blvd., Suite G Winston-Salem NC 27103	Common	08/18/2026	229338	314462.14

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Pereira
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)